Operating Metrics 營運指標
Bristol-Myers Squibb Company (BMY) Operating Metrics 營運指標
Bristol-Myers Squibb Company BMY 最近 8 季公司營運 KPI、指標定義、跨期趨勢與官方來源。
資料截至：2026-06-30
最新營運指標
- Growth Portfolio Revenue
- $28,037M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Opdivo Revenue
- $9,856M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Opdivo Qvantig Revenue
- $624M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Orencia Revenue
- $3,825M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Yervoy Revenue
- $2,969M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Reblozyl Revenue
- $2,571M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Breyanzi Revenue
- $1,646M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
- Opdualag Revenue
- $1,293M · 2026-06-30 來源：Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company、Bristol-Myers Squibb Company
季度趨勢
| 指標 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|---|---|---|---|
| Growth Portfolio Revenue | $7,560M | $6,227M | $7,393M | $6,857M | $6,596M | $5,563M | $6,363M | $5,812M |
| Opdivo Revenue | $2,485M | $2,146M | $2,693M | $2,532M | $2,560M | $2,265M | $2,479M | $2,360M |
| Opdivo Qvantig Revenue | $261M | $163M | $133M | $67M | $30M | $9M | — | — |
| Orencia Revenue | $1,034M | $818M | $1,009M | $964M | $963M | $770M | $1,000M | $936M |
| Yervoy Revenue | $769M | $651M | $810M | $739M | $728M | $624M | $675M | $642M |
| Reblozyl Revenue | $735M | $555M | $666M | $615M | $568M | $478M | $547M | $447M |
| Breyanzi Revenue | $484M | $411M | $392M | $359M | $344M | $263M | $263M | $224M |
| Opdualag Revenue | $349M | $295M | $350M | $299M | $284M | $252M | $254M | $233M |
| Camzyos Revenue | $416M | $314M | $353M | $296M | $260M | $159M | $223M | $156M |
| Zeposia Revenue | $169M | $118M | $160M | $161M | $150M | $107M | $158M | $147M |
資料來源
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 · Bristol-Myers Squibb Company · 2026-07-30
- Bristol Myers Squibb Reports First Quarter Financial Results for 2026 · Bristol-Myers Squibb Company · 2026-04-30
- Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 · Bristol-Myers Squibb Company · 2026-02-05
- Bristol Myers Squibb Reports Third Quarter Financial Results for 2025 · Bristol-Myers Squibb Company · 2025-10-30
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2025 · Bristol-Myers Squibb Company · 2025-07-31
- Bristol Myers Squibb Reports First Quarter Financial Results for 2025 · Bristol-Myers Squibb Company · 2025-04-24
- Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024 · Bristol-Myers Squibb Company · 2025-02-06
- Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 · Bristol-Myers Squibb Company · 2024-10-31